News and Comments

Pharmacyclics: When the Power of Biotechs' Pipelines Overshadows the Market’s influence on the Firms' Values.

  Thursday, February 23, 2012

Pharmacyclic’s (PCYC) story is one of a few where the power of pipeline drugs has overshadowed the stock market’s technical influence on the biotech companies’ values. In other words, in the case of Pharmacyclics, investors should be looking for something extraordinary in the firm’s pipeline, in its choices of its programs, in its plans and strategies in developing its pipeline products and its capability of executing its plans and reaching its goals. Pharmacyclics’ Bruton’s tyrosine Kinase (BTK) inhibitor PCI-32765 therapeutic is unique. In December 2011, Pharmacyclics was granted U.S. patent that testifies to the drug’s exceptionality. It is, indeed, the first irreversible inhibitor in the BTK zone.     More...

Illumina, Roche and Fairness

  Thursday, February 09, 2012

Illumina (ILMN) is occupying the center stage these days. Roche’s persistent attempts to acquire ILMN, has opened investors’ eyes on the importance of this firm’s technology in moving away from the road of stagnation to that of innovation. Innovation is the insurance that guarantees the survival and growth of the drug companies in the future that has already begun. Illumina’s technologies and marketed state-of-the-art sequencers and gene analyzers have been a major contributor to the flourishing of information about the origins of diseases at the molecular level.  This capability, which lured Roche, was overlooked by Wall Street investors who have recently caused a selloff in the stock for theorized reasons. The real value of Illumina resides in its indispensability as the cornerstone of future advancement in medical diagnosis and treatment. With all the new-targeted drugs on the market and in the firms’ pipelines, the current diagnostic and treatment statuses are still far from perfect. More...

Recent Postings



Trastuzumab-DM1 ZALTRAP™ Auspex (ASPX) HALOZYME (HALO) Dynavax (DVAX) Anacor (ANAC) Merck (MRK) REGULUS (RGLS) IDERA (IDRA) Ridaforolimus ISIS (ISIS) Inovio (INO) VANDA (VNDA) Advaxis (ADXS) ADVENTRIX (ANX) GUARDIAN HEALTH Dendreon (DNDN) Anadys (ANDS) Sarepta (SRPT) PORTOLA (PTLA) PTC Therapeutics (PTCT) Velcade (bortezomib) Sanofi (SNA) Vitae Pharmaceuticals (VTAE) Genentech Aimmune Therapeutics (AIMT) Ionis (IONS) SUNESIS PHARMACEUTICALS (SNSS) Zerenex Bellicum (BLCM) Galena (GALE) Multiple Myeloma Onyx (ONXX) Human Longevity (HLI) NANTKWEST (NK) AERIE PHARMACEUTICALS Amgen (AMGN) Rapamune KERYX (KERX) Micromet (MITI) Biocryst (BCRX) Seattle Genetics (SGEN) SYNTA (SNTA) C4 Therapeutics Array Pharmaceuticals (ARRY) TOKAI (TKAOI) JOUNCE THERAPEUTICS (JNCE) AstraZeneca (AZN) Incyte (INCY) OSI (OSIP) Editas (EDIT) CompuGen (CGEN) MODERNA Spike Therapeutics (ONCE) Endometrial Cancer Intercept (ICPT) Theravance (THRX) CEMPRA (CEMP) galapagos (GLPG) Illumina (ILMN) Theravance Bio Pharma (TBPH) Benlysta (belimumab) Human Genome Sciences (HGSI) Ziofpharm (ZIOP) Jazz Pharmaceuticals (JAZZ) Herceptin GlaxoSmithKline (GSK) Tysabri INNOVIVA (INVA) Intrexon (XON) Abbott Laboratories (ABT) Prosensa (RNA) Telaprevir AGOS (ARGS) Sanofi-Aventis (SAN) ARCA (ABIO) CRISPR Therapeutics (CRSP) Alder Biopharmaceuticals (ALDR) Ariad (ARIA) Elan (ELN) Roche (ROCHE) Sequenom (SQNM) Ocular Therapeutix (OCUL) NOVOCURE (NVCR) ImmunoGen (IMGN) RenenxBio (RGNX) ARGOS (ARGS) Global Cell Therapeutics (GBT) ACADIA (ACAD) Exelixis (EXEL) Bristol-Myers Squibb (BMY) Agenus (AGEN Cytokinetics (CYTK) Regeneron (REGN) Roche (RHHBY) NEKTAR (NKTR)) Intermune (ITMN) Vertex (VRTX) Sangamo (SGMO) Xoma (XOMA) Adaptimmune (ADAP) Biogen Idec (BIIB) Gilead (GILD) Alnylam (ALNY) Prolor Biotech (PBTH) KITE (KITE) Mirati Therapeutics (MRTX) Revlimid (lenolidamide) JUNO (JUNO) ABBVIE (ABBV) Pluristem (PSTI) BIOMARIN (BMRN) Sanofi (SNY) Valeant Pharmaceuticals International (VRX) Idenix (IDIX) Agenus (AGEN) SERES THERAPEUTICS (MCRB)